Candidate vaccine, SCB-2019

BIOLOGICAL4 trials

Sponsors

Zhejiang Clover Biopharmaceuticals, Inc., Clover Biopharmaceuticals AUS Pty

Conditions

COVID-19

Phase 1

Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults

CompletedNCT05228314

Clover Biopharmaceuticals AUS PtyCOVID-19

Start: 2022-05-30End: 2023-04-23Updated: 2023-07-03

Phase 2

Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China

Zhejiang Clover Biopharmaceuticals, Inc.COVID-19

Start: 2021-08-10End: 2022-11-15Updated: 2022-03-10

Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age

WithdrawnNCT05193279

Clover Biopharmaceuticals AUS PtyCOVID-19

Start: 2022-10-05End: 2022-12-15Updated: 2023-03-24

Phase 3

Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

CompletedNCT05188677

Clover Biopharmaceuticals AUS PtyCOVID-19

Start: 2022-06-13End: 2023-06-06Updated: 2023-08-24

Related Papers

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults

The Journal of Infectious Diseases2023-07-138 citations